Leronlimab: New PrEP & treating. Including AIDS.
Post# of 157719
(Total Views: 885)
Posted On: 01/28/2025 8:02:55 PM
Leronlimab: New PrEP & treating.
Including AIDS.
WOW!
[0147] Patients may also be administered a CCR5 binding agent in anticipation of exposure to HIV, upon exposure to HIV, at the initial detection of infection with HIV, upon the development of new symptoms after infection, or during any period of HIV infection, including AIDS.
[0006]:
Similarly, use of ART in HIV-negative individuals as PrEP results in unwanted side effects that reduce adherence. Therefore, the development of new user-friendly PrEP and HIV suppression regimens, particularly with simplified dosing regimens that lack unwanted negative side effects, is an urgent global health need.
[0128] A pharmaceutical composition may be formulated in the form of a solid, semi-solid or liquid composition. Solid compositions may include powders and tablets.
[0129] The pharmaceutical compositions described herein can be formulated for oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal administration. The term “parenteral”, as used herein, includes subcutaneous, intravenous, intramuscular, intrasternal, and intratumoral injection or infusion techniques. In some embodiments, the pharmaceutical compositions described herein are formulated for administration as an injection, e.g., an intravenous or subcutaneous injection.
[0146] Patients or patients that can be treated by CCR5 binding agents of the present disclosure include, but are not limited to, a mammal, such as human or non-human primates (e.g., monkeys and apes). In embodiments, the patient is human. The patient can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric.
[0147] Patients may also be administered a CCR5 binding agent in anticipation of exposure to HIV, upon exposure to HIV, at the initial detection of infection with HIV, upon the development of new symptoms after infection, or during any period of HIV infection, including AIDS.
https://www.patentguru.com/assignee/cytodyn-inc
Including AIDS.
WOW!
[0147] Patients may also be administered a CCR5 binding agent in anticipation of exposure to HIV, upon exposure to HIV, at the initial detection of infection with HIV, upon the development of new symptoms after infection, or during any period of HIV infection, including AIDS.
[0006]:
Similarly, use of ART in HIV-negative individuals as PrEP results in unwanted side effects that reduce adherence. Therefore, the development of new user-friendly PrEP and HIV suppression regimens, particularly with simplified dosing regimens that lack unwanted negative side effects, is an urgent global health need.
[0128] A pharmaceutical composition may be formulated in the form of a solid, semi-solid or liquid composition. Solid compositions may include powders and tablets.
[0129] The pharmaceutical compositions described herein can be formulated for oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal administration. The term “parenteral”, as used herein, includes subcutaneous, intravenous, intramuscular, intrasternal, and intratumoral injection or infusion techniques. In some embodiments, the pharmaceutical compositions described herein are formulated for administration as an injection, e.g., an intravenous or subcutaneous injection.
[0146] Patients or patients that can be treated by CCR5 binding agents of the present disclosure include, but are not limited to, a mammal, such as human or non-human primates (e.g., monkeys and apes). In embodiments, the patient is human. The patient can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric.
[0147] Patients may also be administered a CCR5 binding agent in anticipation of exposure to HIV, upon exposure to HIV, at the initial detection of infection with HIV, upon the development of new symptoms after infection, or during any period of HIV infection, including AIDS.
https://www.patentguru.com/assignee/cytodyn-inc
(11)
(0)